Alfuzosin +/- propiverine (10 or 20 mg/dose) in men with lower urinary tract symptoms and overactive bladder

Trial Profile

Alfuzosin +/- propiverine (10 or 20 mg/dose) in men with lower urinary tract symptoms and overactive bladder

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Propiverine (Primary) ; Alfuzosin
  • Indications Lower urinary tract symptoms; Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2014 Results published in the International Journal of Clinical Practice.
    • 06 May 2013 Results presented at the 108th Annual Meeting of the American Urological Association.
    • 22 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top